ARROWHEAD PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 14.66 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 14.66M shares, a 146.62% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.68M shares, a 126.22% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-12-31 was 1.66M shares, a 63.70% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 5.95M shares, a 25.73% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.02M shares, a 5.97% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 4.74M shares, a 16.88% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.05M shares, a 4.32% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.88M shares, a 88.32% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 14.66M shares 10-Q · filed 2026-08-04 | 14.66M shares 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | 13.68M shares 10-Q · filed 2026-05-07 | 10.04M shares 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | 1.66M shares 10-Q · filed 2026-02-05 | |||
| 2025-09-30 | 5.02M shares 10-K · filed 2025-11-25 | |||
| 2025-06-30 | 5.95M shares 10-Q · filed 2026-08-04 | 5.53M shares 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | 6.05M shares 10-Q · filed 2026-05-07 | 5.32M shares 10-Q · filed 2026-05-07 | ||
| 2024-12-31 | 4.58M shares 10-Q · filed 2026-02-05 | |||
| 2024-09-30 | 4.74M shares 10-K · filed 2025-11-25 | |||
| 2024-06-30 | 4.73M shares 10-Q · filed 2025-08-07 | 4.77M shares 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 4.01M shares 10-Q · filed 2025-05-12 | 4.59M shares 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | 3.54M shares 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | 4.05M shares 10-K · filed 2025-11-25 | |||
| 2023-06-30 | 3.47M shares 10-Q · filed 2024-08-08 | 4.02M shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 4.35M shares 10-Q · filed 2024-05-09 | 4.07M shares 10-Q · filed 2024-05-09 | ||
| 2022-12-31 | 3.33M shares 10-Q · filed 2024-02-06 | |||
| 2022-09-30 | 3.88M shares 10-K · filed 2024-11-26 | |||
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-02 | |||
| 2021-09-30 | 2.06M shares 10-K · filed 2023-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |